{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:19:20Z","timestamp":1786119560443,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,20]]},"DOI":"10.1097\/qad.0b013e32834403cd","type":"journal-article","created":{"date-parts":[[2011,2,3]],"date-time":"2011-02-03T00:53:27Z","timestamp":1296694407000},"page":"541-542","source":"Crossref","is-referenced-by-count":10,"title":["Drug interactions between voriconazole, darunavir\/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia"],"prefix":"10.1097","volume":"25","author":[{"given":"Junine","family":"Toy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gigu\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Kravcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles JL","family":"la Porte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-19-20210130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","article-title":"Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir","volume":"80","author":"Mikus","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R3-19-20210130","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1345\/aph.1L607","article-title":"Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis","volume":"43","author":"Carbonara","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R4-19-20210130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2125.2007.03085.x","article-title":"Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers","volume":"65","author":"Damle","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R5-19-20210130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0091270007309703","article-title":"Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects","volume":"48","author":"Liu","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R6-19-20210130","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/AAC.00526-07","article-title":"Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects","volume":"51","author":"Liu","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-19-20210130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R13-19-20210130","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/QAD.0b013e3282170ab1","article-title":"Pharmacokinetics and antiretroviral response to darunavir\/ritonavir and etravirine combination in patients with high-level viral resistance","volume":"21","author":"Boffito","year":"2007","journal-title":"AIDS"},{"key":"R14-19-20210130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R15-19-20210130","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/135965350701200511","article-title":"Pharmacokinetics of darunavir\/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers","volume":"12","author":"Scholler-Gyure","year":"2007","journal-title":"Antivir Ther"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-201102200-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:50:55Z","timestamp":1786042255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-201102200-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,20]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32834403cd","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2,20]]}}}